Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
O00238
UPID:
BMR1B_HUMAN
Alternative names:
-
Alternative UPACC:
O00238; B2R953; B4DSV1; P78366
Background:
The Bone morphogenetic protein receptor type-1B plays a pivotal role in skeletal development and repair, mediating cellular responses to growth factors. It is integral in the signaling pathway that influences chondrocyte differentiation and bone formation.
Therapeutic significance:
Linked to Acromesomelic dysplasia 3, Brachydactyly A2, and Brachydactyly A1, D, this receptor's genetic variants underscore its critical role in limb development. Targeting its pathway offers a promising avenue for correcting skeletal malformations.